[1]
T., Nishimoto; S.G., Whaley; N.P., Wiederhold; Q., Zhang; C.M., Yates; W.J., Hoekstra; R.J., Schotzinger; E.P., Garvey; P.D., Rogers Impact of the Major Candida Glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161. Antimicrob. Agents Chemother., 2019, 63(10), e01304-e01319.
[2]
T., Nishimoto; N.P., Wiederhold; S. A., Flowers; Q., Zhang; S. L., Kelly; J., Morschhauser; C. M., Yates; W. J., Hoekstra; R. J., Schotzinger; E. P., Garvey; P. D., Rogers In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-resistant Strains and Clinical Isolates of Candida Albicans. Antimicrob. Agents Chemotherapy, 2019, 63(6), e00341-19/1-e00341-19/1.
[4]
N. P., Wiederhold; L. K., Najvar; E. P., Garvey; S. R., Brand; X., Xu; E. A., Ottinger; A., Alimardanov; W. J., Hoekstra; R. J., Schotzinger; T. F., Patterson The Fungal CYP51 Inhibitor VT-1129 is Efficacious in an Experimental Model of Cryptococcal Meningitis. Antimicrob. Agents Chemotherapy, 2018, 62(9), e01071-18/1-e01071-18/10.
[5]
T.J., Break; J.V., Desai; M., Natarajan; E.M.N., Ferre; C., Henderson; A.M., Zelazny; U., Siebenlist; W.J., Hoekstra; R.J., Schotzinger; E.P., Garvey; M.S., Lionakis VT-1161 Protects Mice against Oropharyngeal Candidiasis Caused by Fluconazole-susceptible and -resistant Candida Albicans. J. Antimicrob. Chemother., 2018, 73(1), 15.
